| Objective In order to provide more evidence sources to the standard treatment for patients with advanced hepatocellular carcinoma, the writer analyze patients'time to progression(TTP) and overall survival (OS) after patients receiving Transcatheter Arterial Chemoembolization (TACE) combined with sorafenib as a treatment of advanced hepatocellular carcinoma (HCC); observe the healing effect of TACE combined Sorafenib , that is, embolization combined with anti-angiogenic treatment for advanced hepatocellular carcinoma; and also analyze the factors that may affect the prognosis and treatment of security.Material and Methods From April 2007 to January 2010, in International Treatment Division of Guangdong Provincial People's Hospital there are 36 patients, 33 male and 3 female had been Pathologically or clinical diagnosis. After receiving Transcatheter Arterial Chemoembolization (TACE) therapy, in the following 3 to 7 days, this group of patients continuously take sorafenib (brand name: Nexavar) (per tablet 200mg), 2 tablets each time, 2 times a day. Every 4 to 8 weeks is called as one period of treatment. Referring to RECIST Evaluation, the writers mainly observe patients'tumor progression (TTP) and overall survival (OS), record adverse events. In this period, patients return hospital to do treatment evaluation and the writer call patients to follow up treatment. Then the writer establishes data base and analysis data by SPSS16.0. Statistical methods include: using life table method to analyze survival rate, using Kaplan-Meier method to analyze all the survival curves, using Log-rank and Breslow (wilcoxon) to compare survival rate of reach group, using Cox Proportional risk model to analyze different influences to treatment. Results Till March, 2010, 14 of 36 evaluable patients died and 22 survive; the median time to tumor progression (mTTP) to 8.62 months (95% CI: 6.51 ~ 10.24 months); the median survival time (mOS) of 12.41 months (95% CI: 9.57 ~ 14.80 months). The single factor analysis shows that different pathological types,BCLC stage,liver function (Child-Pugh score)and whether hepatitis B or not cause between different survival periods significantly. Multi-factor regression model had been used to analyze the relationship between prognosis (P <0.10) and the following four Variables: BCLC stage, whether the pathology had been confirmed HCC, whether hepatitis B or not. The overall survival rate to observation period is 61.1%; 36 patients had been studied, 22 survive. Among the survivals, there is no CR cases, and 1 case PR, 15 patients SD, 6 patients PD; disease control rate (DCR) (CR + PR + SD) is 44.4%. The side effects of taking Sorafenib mainly are hand-foot skin reaction, fatigue, loss of appetite and diarrhea. These side effects can be markedly eased after symptomatic treatment.Conclusion1 Combined with sorafenib treatment may give patients with advanced hepatocellular carcinoma a longer longevity and keep the disease in a steady state. This therapy can be added into the treatments to patients with advanced hepatocellular carcinoma.2 The side effects of taking Sorafenib (Nexavar) could be stand.
|
PDF Full Text Request